Literature DB >> 17109443

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Anne Uyei1, Susan K Peterson, Julie Erlichman, Kristine Broglio, Sandra Yekell, Kathkeen Schmeler, Karen Lu, Funda Meric-Bernstam, Chris Amos, Louise Strong, Banu Arun.   

Abstract

BACKGROUND: Women who are at increased risk for breast and ovarian cancers, especially BRCA1 and BRCA2 mutation carriers, face a myriad of risk-reduction options, including increased surveillance, chemoprevention, prophylactic oophorectomy, and prophylactic mastectomy. However, little is known about which clinical, demographic, or cancer-related factors are associated with risk-reduction interventions.
METHODS: The authors conducted a retrospective review of records for 554 women who had undergone testing at The University of Texas M. D. Anderson Cancer Center between 2000 and 2006 for deleterious BRCA1 and BRCA2 gene mutations. Data were collected on the risk-reduction interventions these women adopted after they underwent genetic testing. These data were tested for associations with demographic and clinical characteristics.
RESULTS: Among the 554 women who underwent genetic testing for BRCA mutation, 78 were found to have a deleterious mutation in the BRCA1 gene, and 54 had a mutation in the BRCA 2 gene. Of the 554 women, 85 underwent prophylactic mastectomy, 30 prophylactic oophorectomy, and 52 both surgeries; 387 women opted for surveillance. Women who had BRCA mutations, a history of breast cancer or ductal carcinoma in situ (DCIS), or previous breast biopsies were more likely to have prophylactic surgery. Women with a family history of ovarian cancer were more likely to undergo prophylactic oophorectomy. Women with a personal history of ovarian cancer or advanced breast cancer were more likely to undergo surveillance only. Women with breast cancer who had had a total mastectomy as part of their prior breast cancer treatment underwent prophylactic mastectomy more frequently than women who either had breast-conserving surgery or no history of breast cancer. In multivariate analysis, only positive BRCA mutation carrier status was associated with having had prophylactic surgery. In addition, breast cancer history was significantly associated with prophylactic mastectomy.
CONCLUSIONS: Women who were BRCA carriers, women who had a history of breast cancer, DCIS, or breast biopsy, or had a family history of ovarian cancer were more likely to have undergone surgery for cancer risk reduction. Women with ovarian cancer or advanced breast cancer were more likely to have undergone surveillance. Copyright 2006 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109443     DOI: 10.1002/cncr.22352

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation.

Authors:  Dongwon Kim; Eunyoung Kang; Euijun Hwang; Young Sun; Yoonsun Hwang; Cha Kyong Yom; Kidong Kim; Jae Hong No; Yong-Beom Kim; Sung-Won Kim
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

2.  Dose-response effects of aerobic exercise on estrogen among women at high risk for breast cancer: a randomized controlled trial.

Authors:  Kathryn H Schmitz; Nancy I Williams; Despina Kontos; Susan Domchek; Knashawn H Morales; Wei-Ting Hwang; Lorita L Grant; Laura DiGiovanni; Domenick Salvatore; Desire' Fenderson; Mitchell Schnall; Mary Lou Galantino; Jill Stopfer; Mindy S Kurzer; Shandong Wu; Jessica Adelman; Justin C Brown; Jerene Good
Journal:  Breast Cancer Res Treat       Date:  2015-10-28       Impact factor: 4.872

3.  Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.

Authors:  Se Ik Kim; Myong Cheol Lim; Dong Ock Lee; Sun-Young Kong; Sang-Soo Seo; Sokbom Kang; Eun Sook Lee; Sang-Yoon Park
Journal:  J Cancer Res Clin Oncol       Date:  2015-10-05       Impact factor: 4.553

4.  Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.

Authors:  Allison W Kurian; Bronislava M Sigal; Sylvia K Plevritis
Journal:  J Clin Oncol       Date:  2009-12-07       Impact factor: 44.544

5.  Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma.

Authors:  Shannon N Westin; Charlotte C Sun; Karen H Lu; Kathleen M Schmeler; Pamela T Soliman; Robin A Lacour; Kristin G Johnson; Molly S Daniels; Banu K Arun; Susan K Peterson; Diane C Bodurka
Journal:  Cancer       Date:  2010-12-29       Impact factor: 6.860

6.  Choice of management of southern Chinese BRCA mutation carriers.

Authors:  Ava Kwong; Connie H N Wong; Catherine Shea; Dacita T K Suen; Catherine L Y Choi
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

7.  Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center.

Authors:  K Ready; B K Arun; K M Schmeler; A Uyei; J K Litton; K H Lu; C C Sun; S K Peterson
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

8.  Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress.

Authors:  J O Culver; C D Brinkerhoff; J Clague; K Yang; K E Singh; S R Sand; J N Weitzel
Journal:  Clin Genet       Date:  2013-02-20       Impact factor: 4.438

9.  Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.

Authors:  Gabriel N Mannis; Julia E Fehniger; Jennifer S Creasman; Vanessa L Jacoby; Mary S Beattie
Journal:  JAMA Intern Med       Date:  2013-01-28       Impact factor: 21.873

10.  Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes.

Authors:  Suzanne C O'Neill; Christine Rini; Rachel E Goldsmith; Heiddis Valdimarsdottir; Lawrence H Cohen; Marc D Schwartz
Journal:  Psychooncology       Date:  2009-10       Impact factor: 3.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.